Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
Merck CEO on Winrevair Approval, Obesity Drug, Health Costs
默沙东首席执行官谈Winrevair的批准、肥胖药物、健康成本
Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphic.)
默沙东董事长兼首席执行官Robert M. Davis讨论了美国批准Winrevair的情况,Winrevair是一种治疗罕见、危险的高血压的新疗法。戴维斯在彭博电视台发表讲话时还评论了默克开发的抗肥胖药物和医疗费用。(对视频进行了编辑,删除了不正确的图形。)